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A B S T R A C T
DNA polymerase gamma (POLG) is the replicative polymerase responsible for maintaining mitochondrial DNA
(mtDNA). Disorders related to its functionality are a major cause of mitochondrial disease. The clinical spectrum
of POLG syndromes includes Alpers-Huttenlocher syndrome (AHS), childhood myocerebrohepatopathy spectrum
(MCHS), myoclonic epilepsy myopathy sensory ataxia (MEMSA), the ataxia neuropathy spectrum (ANS) and
progressive external ophthalmoplegia (PEO). We have collected all publicly available POLG-related patient data
and analyzed it using our pathogenic clustering model to provide a new research and clinical tool in the form of
an online server. The server evaluates the pathogenicity of both previously reported and novel mutations. There
are currently 176 unique point mutations reported and found in mitochondrial patients in the gene encoding the
catalytic subunit of POLG, POLG. The mutations are distributed nearly uniformly along the length of the primary
amino acid sequence of the gene. Our analysis shows that most of the mutations are recessive, and that the
reported dominant mutations cluster within the polymerase active site in the tertiary structure of the POLG
enzyme. The POLG Pathogenicity Prediction Server (http://polg.bmb.msu.edu) is targeted at clinicians and
scientists studying POLG disorders, and aims to provide the most current available information regarding the
pathogenicity of POLG mutations.
1. Introduction
DNA polymerase gamma is the enzyme responsible for replicating
and maintaining mitochondrial DNA (reviewed in [15,16]). The func-
tional, holoenzyme form of POLG is a heterotrimer consisting of a
catalytic subunit (POLGA) and a dimeric accessory subunit (POLGB).
POLGA carries three catalytic activities: 5′−3′ DNA polymerase, 3′−5′
exonuclease and 5′-deoxyribose phosphate lyase. POLGB enhances DNA
binding, catalysis and holoenzyme processivity. Mutations in POLG are
associated with a wide range of human disorders that exhibit shared
and progressive phenotypes (reviewed in [46]). The POLG disorders
range from prenatally-fatal conditions and severe infantile onset
disorders, such as Alpers disease (Alpers-Huttenlocher syndrome), to
milder, late-onset conditions such as progressive external ophthalmo-
plegia, and are described collectively as POLG syndromes.
POLG mutations are relatively rare, with an estimated carrier
frequency of 1/100 individuals in the Western world [11]. Most are
recessive, and symptoms typically manifest only in compound hetero-
zygous patients. Although the symptoms and severity of the conditions
vary widely, all share a few common features: they largely aﬀect tissues
with high energy demand, such as in the nervous system, muscle and
liver, and they are all progressive conditions that show direct correla-
tion between age of onset and the severity of the condition [9].
To date, 176 unique POLG missense mutations in mitochondrial
patients have been reported in the literature. Typically, POLG patients
carry either homozygous or compound heterozygous POLG mutations,
though some dominant pathogenic mutations exist. We have previously
mapped the mutations onto the tertiary structure of POLGA in the apo-
enzyme form (PDB ID: 3IKM), and shown that the pathogenic mutations
cluster into ﬁve distinct regions that we have termed Alpers clusters 1–5
([6,9], Fig. 1). Furthermore, we reported that the cluster mapping of
POLG mutations shows a direct genotype-phenotype relationship [9].
Cluster 1 consists of the polymerase active site of POLGA and its
environs. Cluster 2 includes residues of the upstream DNA binding
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channel, mutations in which are likely to alter DNA binding aﬃnity and
the overall processivity of the holoenzyme. Though the functionality of
Cluster 3 remains undetermined, its location in the structure suggests
that it may play a role in partitioning the 3′-end of the DNA primer
strand between the polymerase and exonuclease active sites. Mutations
in Cluster 3 are likely to aﬀect both DNA binding aﬃnity and catalytic
activity. A recent study has also suggested that this region may be
involved in functional interaction with the mtDNA helicase [31].
Cluster 4 contains the fewest residues and is located at the interface
of the catalytic subunit with the distal accessory subunit. This interac-
tion has not been characterized extensively, but it is implicated to serve
an important role in enhancing enzyme processivity [26]. Residues in
Cluster 5 lie within the intrinsic processivity (IP) subdomain of the
spacer domain of the catalytic subunit, and based on mutational
analysis are suggested to be involved in protein-protein interactions
[23]. The ﬁve Alpers clusters represent both structural and functional
modules of POLG and are thus hot spots for pathogenic mutations.
Conversely, mutations that lie outside of the clusters are substantially
less likely to be pathogenic.
Our clustering model demonstrates that the age of onset of
numerous symptoms correlates strongly with the severity of the
syndrome and the range of symptoms that are manifest (see Fig. 5,
[9]). For example, the most severe form of POLG syndrome, MCHS
(typical age of onset from birth to three years), includes patients that
present with symptoms such as hypotonia, developmental delay,
gastrointestinal dysfunction and hepatopathy. Patients diagnosed with
AHS (typical age of onset from a few months after birth to 16 years)
share most of these symptoms, but are also more likely to experience
epileptic seizures. MEMSA patients (typical age of onset 13 to 25 years
of age) are in most cases diagnosed with myopathies, neuropathies and
ataxia. Patients diagnosed with ANS (typical age of onset from 15 to
middle-age) show a wide variety in their symptoms, including symp-
toms from both the MEMSA and PEO patient groups. Finally, patients
with PEO (typical age of onset from 30 years and above) represent the
least severe end of the spectrum, and present with symptoms such as
diplopia and ptosis.
2. Results
2.1. POLG pathogenicity prediction server
We have gathered all available patient case reports identifying
POLG mutations from public sources and created an online database for
providing easy access to these data. The database and an online server,
known as the “POLG Pathogenicity Prediction Server,” are available at
http://polg.bmb.msu.edu. For each patient case report, we have
collated the mutations identiﬁed, the reported age of onset of the
symptoms manifested, the clinical description of the patients and
source of the data. Patient gender and information on administration
of valproic acid is also included where available. The current database
contains 681 patient case reports, with 176 unique missense mutations
and 215 unique combinations of pathogenic mutations (Table 1). The
large majority of patient cases (546, 80.2%) identify either compound
heterozygous or homozygous POLGmutations. The remaining 135 cases
(19.8%) report heterozygous variants that are thus putatively-dominant
mutations.
In combination with our pathogenic clustering model [6,9], the
patient data has enabled us to make statistical predictions about the
severity and age of onset of symptoms for patients with both known and
novel mutations. The server features a mutation query interface where
the user can enter the POLG mutations identiﬁed in a patient (Fig. 2).
The server then displays the cluster mapping of the input mutations and
shows any existing patient cases. The statistical information also
includes the allelic combinations in which the mutations have been
reported. If other members of the family are not available for analysis,
this information may be helpful in determining whether the input
Fig. 1. Structural model of the POLG holoenzyme in complex with primer-template DNA. In the three-dimensional ternary complex of POLG, the pathogenic clusters in the catalytic core,
POLGA, form ﬁve distinct functional regions [6]. Upper panel, the structure modeled after PDB structure 4ZTU [39] illustrates the pathogenic clusters of POLGA colored as green for
Cluster 1, yellow for Cluster 2, red for Cluster 3, blue for Cluster 4 and cyan for Cluster 5. Lower panel, subclusters are distributed throughout the primary amino acid sequence of the
POLGA polypeptide. Subclusters are assigned for each continuous block on the primary amino acid sequence. The accessory subunits, POLGB, are illustrated in light grey (proximal
subunit) and dark grey (distal subunit). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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mutations occur in cis or in trans. Finally, based on the existing cases
with similar cluster-mapping mutations, the server displays an indicator
of the most probable age of onset, which can be used as the basis for a
diagnosis/prognosis for a patient. The server also displays the symp-
toms found in patients with similar cluster combinations of mutations.
An alternate and powerful use of the data is the classiﬁcation of
mutations as likely non-pathogenic variants (SNPs).
The server provides access to the patient and mutation data in
various ways (Fig. 3). For example, the patient cases can be viewed
based on their source reference, mutations, cluster combinations, age of
onset, mutated residue number or closest known mutation (either in
primary sequence or three-dimensional structure). The server also
features data compilation pages, displaying the frequencies of age of
onset and reported symptoms for all existing cluster combinations. The
symptoms are displayed in two ways: as reported in the original case
reports, and grouped into broader categories based on aﬀected tissue
types (as per [9]). Additionally, though they are not used directly in the
statistical predictions of pathogenicity, the server includes primary
sequence-based pathogenicity predictions from PON-P2 [28], and also
the most current population exome sequencing data on POLG from the
ExAC project (Table S1; [7]).
2.2. Adjusting the cluster boundaries
The recently published POLG holoenzyme ternary structure makes it
possible to identify all of the POLGA residues that interact directly with
the DNA ligand. Of the 56 residues shown to interact with DNA, only six
map outside of our previously deﬁned pathogenic clusters. Because
these 56 residues have a clear role in the functionality of POLG to bind
and position the DNA ligand, they have a high risk for producing
deleterious eﬀects if mutated. By extending slightly the borders of four
of our subclusters: 2B, 496–517 (previously 497–517); 2D, 752–769
(previously 752–767); 1F, 1098–1138 (previously 1104–1138); and 3C,
795–807 (previously 804–807), these residues are accommodated
within the deﬁned high-risk locations for mutations in the POLG
structure. Full cluster deﬁnitions as deﬁned previously based on
biochemical, structural and genetic studies [9] are included as supple-
mentary Table S2.
A major diﬀerence between the crystal structures of the apo-
holoenzyme (PDB ID: 3IKM; [19]) and holoenzyme ternary complex
(PDB ID: 4ZTU; [39]) is the positioning of the region constituting
pathogenic Cluster 3D (residues 1047–1096; Fig. 4). We have pre-
viously termed this region the partitioning loop. Cluster 3D carries
several known pathogenic mutations including p.S1080I, p.I1079L,
p.C1077G, p.P1073L, p.G1076V and p.R1096C. In the apoenzyme
structure, the tip of this long looping region extends within ~5 Å of
the polymerase active site, protruding inward from the surface of the
enzyme. In contrast, in the holoenzyme ternary complex structure, the
Table 1
Contents of the POLG Pathogenicity Prediction Server and distribution of
mutations. The majority of patient cases report compound heterozygous muta-
tions.
Total number of patient cases 660
Infantile onset cases 181
Childhood onset cases 103
Juvenile onset cases 85
Adult onset cases 284
Unknown age of onset cases 7
Unique missense mutations 176
Unique pathogenic mutation combinations 215




Fig. 2. The mutation query interface of the POLG Pathogenicity Prediction Server. The server provides statistical predictions of age of onset, and shows the typical symptoms for patients
with mutations that map within pathogenic clusters 1–5. Information about allelic conﬁguration of mutations can be helpful in cases for which pedigrees are not available. The server also
provides direct access to clinical descriptions of patient cases that have similar mutations.
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same region of the loop closest to the polymerase active site in the
apoenzyme structure is on the surface of the polymerase domain at a
distance of> 20 Å from the polymerase active site. Though not
discussed by Yin and collaborators [19,39], the crystal structure in
the proximity of Cluster 3D is apparently highly disordered, and is
missing two stretches of ~30 amino acids, residues 993–1024 and
317–340, suggesting that the structural evaluation of this region will
remain a substantial challenge. In the apo-holoenzyme structure, most
of the pathogenic mutations in Cluster 3D are located between the
polymerase and exonuclease domains, suggesting that modulation of
the exonuclease to polymerase ratio is a possible function of this region
[6]. In addition, in the holoenzyme structure ternary complex, the 5′-
end of the template strand of the DNA ligand exits the polymerase
domain at a site in which interaction with Cluster 3D residues appears
likely. A recent study by Qian et al. [31] reported that pathogenic
mutation p.P1073L, located in cluster 3D, does not aﬀect either the
polymerase or exonuclease activities of POLG, but exhibits deleterious
eﬀects in an assay in which mitochondrial DNA helicase function is
required, suggesting a possible functional interaction between them.
Clearly, further investigation of the structure and function of this region
is warranted.
Fig. 3. Site navigation within the POLG Pathogenicity Prediction Server. The server provides access to collated data by various search interfaces, and provides statistical predictions of
onset of symptoms based on the pathogenic clustering model.
Fig. 4. Positioning of Cluster 3D in the POLG apo-holoenzyme as compared to the holoenzyme ternary complex. Cluster 3D (residues 1047–1096, red surface representation) is located in
a substantially diﬀerent position between the apo-holoenzyme (panel A, PDB ID: 3IKM) and holoenzyme ternary complex (panel B, PDB ID: 4ZTU). The repositioning of Cluster 3D
appears unlikely to represent a conformational change. Rather, this region of the tertiary structure is likely to contain disordered regions, rendering diﬃcult its structural evaluation. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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2.3. Common mutations in the patient data
Three mutations represent the most commonly reported POLG
mutations: p.A467T (c.1399G/A, 228 cases), p.W748S (c.2243G/C,
176 cases) and p.G848S (c.2542G/A, 64 cases). These map to three
diﬀerent clusters (p.G848S, Cluster 1; p.A467T, Cluster 2; p.W748S,
Cluster 5). They have been reported in all possible compound hetero-
zygous combinations as well as in homozygous form, making a
comparative analysis of their observed phenotypes possible (Table 2).
p.A467T and p.W748S have also been reported in heterozygous patients
in eight and two cases, respectively. p.W748S is commonly found in cis
with another mutation, p.E1143G. p.E1143G was assessed previously as
non-pathogenic and potentially compensatory [3,30]. Our analysis
corroborates this assessment as similar ages of onset are reported
among patients homozygous for p.W748S (21 years, 30 cases) and
p.W748S + p.E1143G (22 years, 35 cases). Furthermore, p.E1143G
maps outside of the deﬁned pathogenic clusters.
A comparison of the three mutations shows that p.G848S is
associated with the most pathogenic phenotypes. When found in
compound heterozygous form with p.A467T, the average age of onset
is 1.7 years (± 2.0 years, infantile). By contrast, in compound hetero-
zygous patients carrying p.G848S and p.W748S, the average age of
onset is 5.7 years (± 2.6 years, childhood). A single patient carrying
homozygous p.G848S has been reported with an age of ﬁve years at the
time of examination [40]. Mutation p.G848S has been characterized
biochemically to have a substantially reduced DNA-binding aﬃnity and
very low DNA polymerase activity [18]. A possible explanation for the
lack of additional homozygous p.G848S patient case reports is that most
of them result in prenatal mortality.
Patients carrying mutations p.A467T and p.W748S show similar
ages of onset: the average age of onset for homozygous patients is
19.9 years (± 13.7) for p.A467T and 21.4 (± 10.4) years for
p.W748S. These data corroborate the ﬁndings reported in a recent
study on the extensive clinical heterogeneity of homozygous p.A467T
patients [32]. Interestingly, compound heterozygous cases with geno-
type p.A467T/p.W748S manifest later, at ~25 years of age, suggesting
that enzymes carrying deleterious mutations in diﬀerent clusters could
have compensatory properties. The heterozygous cases of p.A467T (ﬁve
cases) and p.W748S (two cases) represent a small fraction of known
carriers. The ExAC genome mapping project reports global population
frequencies of 0.052% for p.A467T and 0.083% for p.W748S [7].
Moreover, in independent studies, p.A467T was found in the Belgian
population at a particularly high frequency of 0.6% [43] and likewise,
p.W748S was found in the Finnish population at a frequency of 0.8%
[12]. By comparison, the frequency of p.W748S in the Finnish popula-
tion is 0.57% in the ExAC dataset. These data alone argue that a
dominant status for these mutations is unlikely in the absence of other
genetic or environmental factors predisposing the patients to a mito-
chondrial disorder.
Biochemical studies show that in comparison to the wild type POLG,
the p.A467T mutant enzyme exhibits moderate to substantially reduced
DNA binding aﬃnity resulting in similarly reduced polymerase proces-
sivity [25]. The p.W748S mutant enzyme was shown in one study to
exhibit substantially reduced DNA binding aﬃnity and polymerase
processivity [3], whereas another reported enzymatic properties similar
to the wild type enzyme [30]. A summary of the biochemical
characterization of these mutations is included as Table S3.
2.4. Mutations yielding putatively non-functional POLG
Mutations that introduce frameshifts, premature stop codons, exon
skipping or large deletions are likely to inactivate POLG function
entirely and/or impact its folding, subunit interaction or stability.
Structural perturbations would likely render the enzyme subject to
cellular turnover. We have grouped together on the server mutations
that would result in a putatively non-functional (PNF) POLG. Several of
them have been characterized biochemically, corroborating such a non-
functional status, though some may retain limited DNA binding
capability or other partial functionality [17,34]. Patients with com-
pound heterozygous PNF mutations that carry the three most com-
monly reported POLG mutations typically manifest with very severe,
infantile onset conditions. For example, 14 patients with a compound
heterozygous p.A467T/PNF genotype manifested symptoms at an
average age of onset of 1.5 years. For four reported patients with a
p.W748S/PNF genotype, the average age of onset is 1.7 years. No
patients have been reported with p.G848S/PNF mutations. These data
argue that the enzyme level produced from the single, partially-
functional allele is a crucial factor in these patients, as compared with
the more moderate phenotypes exhibited by the compound hetero-
zygous and homozygous cases in which pA467T, p.W748S or p.G848S
are present. Several exceptions have been reported. A single patient
carrying A467T + E873X/E873X (A467T + PNF/PNF) survived until
Table 2
Common POLG mutations. The three most commonly reported POLG mutations, p.A467T, p.W748S and p.G848S, have been reported in all possible compound heterozygous
combinations, as well as in homozygous form. Heterozygous case reports are rare for p.A467T and p.W748S, and there are none for p.G484S. Comparatively, p.G848S appears to occur in
more severe cases, and p.W748S consistently shows a slightly milder phenotype in comparison to p.A467T.
Mutation Clusters Average age of onset
(years)
Standard deviation Number of reported cases
W748S + E1143G/wt 5 + SNP/– 59.0 4.0 2 (1 outliera)
A467T/wt 2/– 42.8 11.2 5 (1 outlierb)
W748S/W748S 5/5 21.4 10.4 27 (1 outlierc)
W748S + E1143G/W748S + E1143G 5 + SNP/5 + SNP 22.1 11.1 35
A467T/A467T 2/2 19.9 13.7 45
G848S/G848S 1/1 5.0 0.0 1
W748S/A467T 5/2 28.7 11.2 27
W748S + E1143G/A467T 5 + SNP/2 21.4 11.7 15
A467T/W748S + K561M 2/5 + 2 0.01 0.0 1
A467T/G848S 2/1 1.7 2.0 22
W748S/G848S 5/1 5.7 2.6 8
A467T/PNF 2/– 1.5 1.0 14 (1 outlierd)
W748S/PNF 5/– 1.7 1.3 5
W748S + Q497H + E1143G/
W748S + Q497H + E1143G
5 + 2 + SNP/5 + 2 + SNP 19.0 4.0 2
W748S + Q497H + E1143G/A467T 5 + 2 + SNP/2 17.0 0.0 1
a Sarzi et al. [47], patient 36 (id: 404). [http://www.ncbi.nlm.nih.gov/pubmed/17452231].
b Galassi et al. [48], (id: 409). [http://www.ncbi.nlm.nih.gov/pubmed/18504126].
c Tzoulis et al. [49], (id: 552). [http://www.ncbi.nlm.nih.gov/pubmed/24841123].
d Martikainen et al. [50], (id: 666). [http://www.ncbi.nlm.nih.gov/pubmed/27111573].
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10 years of age [27]. One possible explanation suggested by the authors
of the report is that the premature stop codons are leaky, and some
functional enzyme is still produced by the PNF allele. Similarly, Roos
et al. [34] reported two brothers with a compound heterozygous
genotype p.T914P/c.3104 + 3A > T (Cluster 1 mutation/splice site
mutation). Molecular analysis showed that skipping of POLG exon 19
caused by c.3104 + 3A > T was incomplete, such that some wild type
POLG was still produced, leading to an ameliorated phenotype with the
patients manifesting symptoms at 20 and 50 years of age. Similar
molecular analyses are warranted to determine which speciﬁc PNF
mutations might still produce some wild type enzyme.
PNF mutations are all recessive, and the PNF carrying enzymes are
likely incapable of competing for DNA binding with wild type POLG at
the mtDNA replication fork. This hypothesis is corroborated by the
presence of asymptomatic carriers in the pedigrees of patient reports.
As such, the PNF enzymes also serve to establish an approximate
baseline for assessing the severity and dominant versus recessive status
of a mutation. Because PNF enzymes are putatively incapable of
contributing to mtDNA replication, a mutation that is present in an
individual in compound heterozygous form with a PNF mutation is
likely to be a recessive mutation that produces an enzyme that is to
some extent capable of mtDNA replication. This assessment supports a
recessive status for two of the most common mutations, p.A467T and
p.W748S, because they have been found in compound heterozygous
form with PNF mutations. The patient data corroborates the biochem-
ical evidence that p.G848S is only marginally more processive than a
PNF enzyme [18], and thus a p.G848S/PNF genotype is not viable.
The patient data supports a model in which each deleterious POLG
mutation aﬀects the overall capacity of the enzyme to replicate and
maintain mtDNA. Although recessive mutations may exert deleterious
eﬀects on enzyme functionality, symptoms are not manifest during the
lifetime of an individual because a single wild type allele is typically
suﬃcient. In both compound heterozygous and homozygous cases, each
mutation may reduce the overall cellular capacity to maintain mtDNA,
such that the most energy-demanding and mitochondria-dense tissues
are aﬀected. The patient data show that homozygous mutations are
similar to compound heterozygous mutations, such that each allele with
one or more deleterious mutations renders the condition more severe as
aging progresses. Moreover, mutations aﬀecting diﬀerent critical
functionalities (and mapping to diﬀerent clusters) of POLG may show
either compensatory or exacerbating eﬀects.
The patient status in the ﬁrst two-to-three years of life appears to be
a critical determinant. The average survival time of patients that
manifest with POLG syndromes under the age of three is on average
under ten months with a maximum of ﬁve years after the time of onset
of symptoms, as evidenced by 144 patient cases in which both the age
of onset and age of death were reported (Fig. 5). The use of valproic
acid to treat patients with epileptic seizures may account for shorter
lifetimes reported at the more severe end of POLG syndromes, because
treatment may lead to hepatotoxicity and acute liver failure [44].
Eﬀects of environmental and cellular stress factors such as infec-
tions, unhealthy lifestyle, malnutrition, sleep deprivation and other
conditions could not be controlled in the patient data evaluated in this
study. In addition to the inconsistent reporting of patient data (age of
onset/age at examination/age of death) to explain the high standard
deviation seen in the data, it is likely that other currently unidentiﬁed
genetic factors contribute to disease progression. In homozygous cases,
the possible eﬀects of consanguinity could also not be controlled.
2.5. Dominant POLG mutations
The POLG Pathogenicity Prediction Server contains 50 unique
missense mutations that have been reported as heterozygous POLG
mutations in a total of 131 individual patients. Patient case reports are
available for examination through the mutation query and patient data
access interfaces on the server, and a list of all pathogenic heterozygous
POLG mutations is also available with hyperlinks to the individual
patient case reports. Based on the clinical data and in the absence of
other explaining factors, these 50 mutations are tentatively assigned as
pathogenic with a dominant inheritance mode. We have assessed the
probability that they are the root cause of the symptoms described in
the reported patient cases by taking into account the full patient dataset
and their pathogenic cluster assignments.
We have subdivided the 50 heterozygous mutations into three
groups as follows. Mutations in patient case reports that are not found
at an elevated frequency in available population data and have been
characterized as putatively-dominant in biochemical studies are cate-
gorized as most likely dominant. For 14 heterozygous mutations, only a
single patient case has been reported, and additional data are required
to conﬁrm a putatively-dominant status. Mutations found in hetero-
zygous patient cases without any other explanatory factors for the
condition of the patients are categorized as having an unclear dominant
pathogenicity. Mutations in which the case report indicated they are
likely not the root cause for the condition of the patient have been
categorized in the least likely dominant group. We have also taken into
account biochemical data and reported asymptomatic carriers when
assigning mutations into this last group. Our classiﬁcation of the 50
heterozygous POLG mutations is discussed below, and is indicated on
the list available on the POLG Pathogenicity Prediction Server.
The majority of the most-likely dominant pathogenic mutations
surround the polymerase active site in the catalytic subunit, POLGA
(Fig. 6). The residues in this region are involved in incoming nucleotide
selectivity, base pairing with the template DNA strand and incorpora-
tion of the incoming deoxynucleotides into the primer DNA strand.
These are the critical steps in DNA strand synthesis, and defects can
impact both the eﬃciency and ﬁdelity of mitochondrial DNA replica-
tion and lead to stalling of the DNA replication fork. Replication stalling
can lead to mtDNA depletion, and result in base substitution, frameshift
and deletion mutations and errors in nucleotide incorporation [37].
Notably, it was shown in a murine model that mitochondria can be
relatively tolerant of point mutations, and a 500-fold increase in point
mutations did not limit the lifespan of the animals [45]. This would
argue that neither the reduced nucleotide selectivity nor defective
exonucleolytic editing observed for some putatively-dominant muta-
tions are likely the sole contributors in dominant pathogenicity. In that
regard, exonucleolytic proofreading has been reported to increase the
ﬁdelity of POLG 20–100 fold depending on the assay used
Fig. 5. Average lifespan after onset of symptoms. POLG syndromes are progressive
conditions, and age of onset correlates directly with the severity of the disease. Patient
data were analyzed in cases for which both the age of onset of symptoms and age of death
were reported, and included 144 patient cases. The use of valproic acid to treat patients
with epileptic seizures may account for shortened lifespans in the data in the more severe
cases of POLG syndromes.
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[14,21,22,29]. It also appears possible that proofreading activity is not
the most critical function of the exonuclease domain; some mutations in
the exonuclease domain result in reduced nucleotide polymerization
rather than defects in proofreading [38], and it has been shown recently
that exonucleolysis by POLGA is required for producing circular double-
stranded DNA [26].
Though all mutations that are most likely to be dominant are
located around the polymerase active site, not all mutations in close
proximity to it are likely to be dominant. These include p.S433C and
p.R1187W. There is only a single case report for p.S433C with an
unspeciﬁed age of onset, and the mother of the patient was reported to
be an asymptomatic carrier [13]. p.R1187W was reported in two cases
in which the family histories do not support an assignment of dominant
inheritance [33,35].
Three mutations, p.G848S, p.T851A and p.R852C, located in a
highly conserved β-hairpin structure (residues 844–856) that lies
between the polymerase and exonuclease domains, were reported as
heterozygous in one in 66, one in four and one in 16 heterozygous
patient cases, respectively. This region of the POLG structure is
important for mispair recognition [39], and is likely to be involved in
facilitating correct DNA binding near the polymerase active site, thus
aﬀecting both the polymerization rate and ﬁdelity of the enzyme.
Because there are many asymptomatic carriers for each of the three
mutations, they are categorized as unlikely-dominant mutations. More-
over, they appear in the available population data with frequencies of
0.016% for p.G848S, 0.008% for p.T851A and 0.0066% for p.R852C
[7]. Though unlikely dominant, they are nonetheless highly pathogenic
when found in compound heterozygous form.
Mutations that lie near the polymerase active site and are categor-
ized as having an unclear dominant status include p.D930N, p.H945L
and p.R953C. Only a single patient case has been reported for p.H945L
with matching symptoms and age of onset typical of dominant POLG
mutations, but with no available family history [4]. p.R953C has been
reported as a heterozygous mutation in only one patient case of four,
without any family background [24] and is reported at a population
frequency of 0.0016% in the ExAC database [7]. p.D930N has been
described as exhibiting dominant-like pathogenicity in a yeast model,
without any corroborative patient data [1].
The most commonly reported POLG mutation presenting with a
dominant inheritance pattern is p.Y955C, with 39 patient case reports.
The onset of symptoms for these patients is in adulthood with an
average age of 35 (± 14.5) years. Residue Y955 is located near the
polymerase active site and maps within pathogenic Cluster 1. Its
location in the POLG structure and the existing biochemical literature
support a critical role in orienting and base pairing of the correct
nucleotide with the template DNA strand [5]. Nucleotide polymeriza-
tion by the variant POLG is reduced and misincorporation rate is
elevated; kinetic analysis documents up to 1300-fold reduction in
nucleotide incorporation ﬁdelity [5]. Typical symptoms of patients
carrying p.Y955C include PEO, muscle weakness and various neurolo-
gical symptoms. Indeed, the most commonly reported symptoms for
patients carrying putatively-dominant mutations are PEO/ptosis and
muscle weakness, reported in 44% and 23% of the heterozygous
patients, respectively (Fig. 7).
The biochemical characterizations reported to date for the puta-
Fig. 6. Heterozygous POLG mutations. Panel A, model of the catalytic subunit of POLG illustrating mutations that have been reported to be heterozygous in the POLG Pathogenicity
Prediction Server database. Mutations for which substantial corroborative evidence indicates dominant inheritance are shown in red spheres, and surround the polymerase active site
(black arrow). Yellow spheres indicate mutations for which there is insuﬃcient data to argue dominant status. Green spheres depict mutations least likely to be dominant. The color status
is not indicative with respect to pathogenicity in compound heterozygous form. Two of the most common pathogenic POLGmutations, p.A467T and p.W748S, are shown in cyan spheres.
Panel B, close-up of the active site of the polymerase domain of POLGA (black arrow). The putatively-dominant mutant residues (red spheres) interact with the incoming dNTP (orange),
template DNA or the catalytic Mg-ions (black spheres). A hotspot for these is on the O-helix, in which every residue facing the polymerase active site has been reported in a heterozygous
POLG patient. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 7. The most commonly reported symptoms of heterozygous POLG patients.
Symptoms in order of commonness in heterozygous patients include ptosis, progressive
external ophthalmoplegia (PEO), muscle weakness, Parkinson's disease and tremors.
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tively-dominant mutations [2,3,10,18, 25,30], combined with the
patient case reports, highlight the fact that the most critical properties
of dominant pathogenic mutations in POLG appear to be severely-
reduced polymerase activity with suﬃcient DNA binding aﬃnity to
compete with wild type enzyme at the mtDNA replication fork (Table
S3).
3. Discussion
We report the development of an online POLG Pathogenicity
Prediction Server. The server represents a comprehensive, interactive
database that complements and extends substantially the online Human
DNA Polymerase gamma Mutation Database (http://tools.niehs.nih.
gov/polg/). POLG data and patient cases are accessible in numerous
ways as described under Results, and additional content is provided by
including analysis by the PON-P2 algorithm [28] and ExAC population
frequency data [7]. Most notably, the POLG Pathogenicity Prediction
Server incorporates our previously described clustering model for
pathogenicity prediction, which was derived by evaluation of biochem-
ical, structural and genetic data on POLG and the related family A
group DNA polymerases, bacterial DNA polymerase I and bacterioph-
age T7 DNA polymerase [6,9]. Because most POLG syndromes result
from the incidence of compound heterozygous mutations, the clustering
analysis of pairs of mutations based on the analysis of currently
available mutations and mutational pairs gives insight into the likely
pathogenicity of novel pairs, and of previously-identiﬁed alleles in
combination with novel alleles. As such, we believe the prediction tool
will be widely applicable as one parameter in the diagnosis of
mitochondrial disorders.
Noteworthy challenges and/or limitations of the dataset include the
varying methods and variety of tests employed in the examination of
patients that have been reported and in particular, in publications prior
to the generalized use of DNA sequencing to evaluate the spectrum of
possible genes and genetic causes for mitochondrial disorders.
Additionally, age of onset may not be reported as the ﬁrst onset of
symptoms; rather, the age of the patient at the time of examination has
sometimes been reported. In view of these challenges, we highlight the
importance of whole exome analysis (see for example [41]) and of
reporting patient cases with full pedigrees and detailed descriptions of
age of onset of symptoms. Though thorough clinical examination may
not be possible for the immediate relatives of the patients, a description
and overall assessment of their wellbeing would prove helpful. Finally,
it is important to document the co-existence of potentially non-
pathogenic polymorphisms such that any impact they might have in
combination with a pathogenic mutation can be assessed appropriately.
Issues related to both intrinsic genetic and biochemical parameters
must be evaluated further as new patient data on pathogenic mutations
emerges. At present, the dataset of available mutations is characterized
by the overrepresentation of the three common pathogenic mutations
p.A467T, p.W748S and p.G848S that are present in composite in 71% of
the 681 case reports. Whereas the relative frequency of new variants
reported will likely remain similar, their absolute number will increase
with streamlined reporting on an international scale. The POLG
Pathogenicity Prediction Server features a contact form that can be
used for pointing out errors in the existing data, notifying the database
administrators of new publications and requesting conﬁdential analysis
of rare POLG mutations.
A potential shortcoming of the pathogenic clustering protocol is a
direct reﬂection of the intrinsic structural and biochemical properties of
POLG and indeed, of all enzymes. Whereas a new variant allele
mapping to a pathogenic cluster is much more likely to be pathogenic
than one that lies outside of a cluster, not all amino acid residues within
a cluster or subcluster have a similar likelihood and/or level of
pathogenicity. This inherent property is dependent strongly on both
the biochemical function of the speciﬁc amino acid and the chemical
nature of the amino acid change induced by the mutation. For example,
an amino acid that is crucial to POLG function such as the catalytic
residues in the pol motifs A, B and C that are conserved among family A
DNA polymerases and which lie in POLG subclusters 1D, 1E and 1F,
respectively, may be either underrepresented or absent in the dataset
because amino acid substitutions are not tolerated in live individuals.
On the other hand, conservative amino acid changes within cluster-
mapping residues may show no clinical phenotypes. In such situations,
use of the residue browser function of the server will provide relevant
information for further evaluation. Nonetheless, in the ‘big picture’
sense, it is clear that combinations of mutations mapping to the pol
domain cluster 1 in combination with those mapping in either the DNA-
binding channel cluster 2 or the putative protein: protein interaction
cluster 5 constitute the bulk of the patient cases (96) manifesting
infantile onset, and involve one or more of the most common mutations
reported. Additionally, nine of 10 putatively-dominant mutations that
we have classiﬁed as most-likely dominant (56 of 57 patient cases
reported) map within the catalytic subclusters of the pol domain, 1D
and 1E. This includes for example, the pathogenic mutation p.Y955C
[10,20,42]. The single mutation mapping outside of cluster 1 is P765T
in cluster 2; though its location in the POLG structure suggests a high
likelihood of dominance, there is only a single case report and no
existing biochemical data.
Biochemical characterization of mutations in conjunction with the
patient data suggests that mutations that impair nucleotide polymer-
ization by POLG without aﬀecting DNA binding carry the highest risk
for dominant inheritance. The low number of reported patient cases for
some of the putatively-dominant mutations and lack of consistent
testing and reporting in patient pedigrees obscures the evaluation of a
likely dominant status. Based on the available genetic, biochemical and
clinical data in our database we have re-evaluated the status of 49
putatively-dominant mutations and divided them into three classes. We
suggest that the 10 mutations that fall within the most-likely dominant
group be considered strongly by clinicians as a root cause of mitochon-
drial dysfunction.
It is well documented that the symptoms and tissue speciﬁcity of
pathogenicity in patients suﬀering from POLG syndromes varies widely,
even among patients carrying the same POLG mutations (see for
example [32]). Nonetheless our analysis shows a clear consistency in
age of onset that does not diﬀer with gender. We also observed an
apparently stronger correlation of symptoms within families. This
observation highlights the likelihood that other genetic components
are contributory and the importance of whole exome analysis in the
evaluation of POLG syndromes, and of mitochondrial disorders in
general to identify such components. Eﬀorts such as Mitochondrial
Disease Sequence Data Resource (MSeqDR) are underway to address
the issue of nuclear genetic modiﬁers [8,36]. Future eﬀorts should also
address the possible contributions of mtDNA genetic background. At
present, our understanding of the disease etiology of POLG syndromes
together with the currently available diagnostic tools should be
beneﬁcial in family planning for couples undergoing genetic testing,
even those with no familial history of mitochondrial disorders.
4. Materials and methods
Patient data deposited into the database and used in this study are
anonymous and collected from publicly available journal articles. The
source of each patient case is stated and available on the server. The
data in the literature is reported in a non-standardized form and
comprises a variety of diﬀerent tests, examinations and details. The
server categorizes each case based on the age of onset of the ﬁrst
symptoms reported into the following age groups: infantile, < 3 years;
childhood, 3–13 years; juvenile, 13–20 years; or adult, ≥20 years. For
reports in which only the age of the patient at the time of examination is
reported, this age was used. If no age for the patient is reported, the age
group is indicated as “unknown.”
Symptoms were categorized based only on the diagnoses provided
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in the report. For conditions such as Alpers syndrome, it might be the
case that nearly all of the known symptoms for this condition have been
reported in a patient case. However, if the diagnosis of Alpers has not
been reported directly, the case has not been deposited as an Alpers
entry. For other conditions such as ataxia, we have accepted terms such
as “movement disorder,” “ataxic gait,” “gait disturbance” and “gait
unsteadiness” as being synonymous.
The output of predictions of pathogenicity provided by the mutation
query interface of the server are based on the pathogenic clustering
model and statistics of existing patient cases with similar cluster-
mapping mutations. The borders of the subclusters have been deﬁned
by available patient data, structural information and biochemical
studies of mutations [6]. The statistical predictions reﬂect directly the
contents of the database, and can be reﬁned as new cases are added.
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